Case reports of patients with ALK-positive NSCLC and brain metastases

Article Properties
  • DOI (url)
    10.36290/xon.2023.013
  • Publication Date
    2023/03/01
  • Journal
    Onkologie
  • Indian UGC (journal)
  • Refrences
    14
  • Petra Zemanová
  • Milada Zemanová
  • Vladimír Černý
Cite
Zemanová, Petra, et al. “Case Reports of Patients With ALK-Positive NSCLC and Brain Metastases”. Onkologie, vol. 17, no. 1, 2023, pp. 57-61, https://doi.org/10.36290/xon.2023.013.
Zemanová, P., Zemanová, M., & Černý, V. (2023). Case reports of patients with ALK-positive NSCLC and brain metastases. Onkologie, 17(1), 57-61. https://doi.org/10.36290/xon.2023.013
Zemanová P, Zemanová M, Černý V. Case reports of patients with ALK-positive NSCLC and brain metastases. Onkologie. 2023;17(1):57-61.
Refrences
Title Journal Journal Categories Citations Publication Date
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial Journal of Thoracic Oncology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
  • Medicine: Medicine (General)
 146 2021
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 208 2018
10.1056/NEJMoa1704795
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases Cancer Chemotherapy and Pharmacology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 173 2014
10.1016/S0140-6736(17)30123-X